To get deals in your inbox each morning, sign up for our Term Sheet newsletter
Venture Capital DealsJuno Therapeutics, a Seattle-based developer of immunotherapies for cancer, has closed its Series A round with $176 million in capital commitments ($145m of which was previously disclosed). Backers include ARCH Venture Partners, Alaska Permanent Fund, Bezos Expeditions and Venrock. Juno's strategic partners are The Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and the MORE
